Zepbound (Tirzepatide) vs Wegovy (Semaglutide): The Complete Comparison

Zepbound (Tirzepatide) vs Wegovy (Semaglutide): The Complete Comparison

Both Zepbound and Wegovy are prescription weight-loss injections that have transformed obesity medicine over the past few years. But they work differently — and the clinical evidence now shows a meaningful gap in outcomes. If you're trying to understand which option might be right for you, this comparison breaks down the science, the data, and what each medication actually does in the body.

Medical disclaimer: This article is for informational purposes only. Both medications are prescription-only and require assessment by a licensed clinician. Speak with a doctor before starting any weight-management programme.

What Is Tirzepatide (Zepbound)?

Tirzepatide is the active ingredient in Zepbound (and Mounjaro, its diabetes-branded equivalent). It is a dual GIP/GLP-1 receptor agonist — meaning it activates two hormonal pathways simultaneously:

• GIP (glucose-dependent insulinotropic polypeptide): Regulates fat metabolism, improves insulin sensitivity, and may increase the sensitivity of fat cells to the weight-reducing effects of GLP-1.
• GLP-1 (glucagon-like peptide-1): Slows gastric emptying, promotes satiety, reduces appetite signalling in the brain, and lowers post-meal blood glucose.

The combination of both mechanisms is central to why tirzepatide has outperformed existing GLP-1 monotherapies in head-to-head trials.

Dose range: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (weekly injection)

What Is Semaglutide (Wegovy)?

Semaglutide is the active ingredient in Wegovy (and Ozempic, its diabetes-branded version). It is a GLP-1 receptor agonist — it binds only to GLP-1 receptors, not GIP receptors.

Semaglutide was the first injectable GLP-1 agonist approved specifically for chronic weight management, and it established the benchmark that tirzepatide has now surpassed. Its mechanism includes reduced appetite, slower gastric emptying, and improved insulin regulation.

Dose range (Wegovy): 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (weekly injection)

The Key Difference: One Hormone vs Two

The dual mechanism matters clinically. GIP receptors are found in adipose tissue, and when activated alongside GLP-1, they appear to amplify the body's response to energy restriction — producing greater fat loss than GLP-1 stimulation alone.

What the Clinical Trials Show

SURMOUNT-5: The Head-to-Head Trial

The landmark SURMOUNT-5 trial (Garvey et al., New England Journal of Medicine, 2025) is the most important data point in this comparison. It was a randomised, double-blind, active-controlled trial that directly compared tirzepatide (10 mg and 15 mg) against semaglutide 2.4 mg in adults with obesity or overweight with at least one weight-related comorbidity, without type 2 diabetes.

Key results at 72 weeks:

• Tirzepatide: Mean body weight reduction of ~20.2%
• Semaglutide 2.4 mg: Mean body weight reduction of ~13.7%
• Tirzepatide produced approximately 47% greater relative weight loss versus semaglutide
• A significantly higher proportion of tirzepatide participants achieved ≥25% body weight loss

This is a direct, controlled comparison — not cross-trial extrapolation. The superiority of tirzepatide was statistically significant across both doses tested.

STEP 1: Semaglutide's Pivotal Trial

The STEP 1 trial (Wilding et al., NEJM, 2021) established semaglutide 2.4 mg as a meaningful advance over previous weight-loss medications. In 1,961 adults with obesity (without T2D), semaglutide produced:

• Mean weight reduction of ~14.9% versus ~2.4% with placebo
• 86.4% of participants achieving ≥5% weight loss
• 69.1% achieving ≥10% weight loss

STEP 1 demonstrated that semaglutide was significantly more effective than any prior approved weight-loss pharmacotherapy. SURMOUNT-5 has since shown tirzepatide raises the bar further.

Side Effect Profile: How Do They Compare?

Both medications share a similar side-effect profile because they both activate GLP-1 receptors. The most common adverse effects are gastrointestinal:

Important contraindications for both:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to the active ingredient
• Pregnancy or planned pregnancy

The GI side effects are typically most pronounced during dose escalation and tend to diminish as the body adjusts. Slow titration protocols are standard practice for this reason.

Muscle Loss: A Shared Concern

Rapid weight loss from any cause — diet, surgery, or medication — can result in loss of lean muscle mass alongside fat. Studies on both medications show that a significant proportion of weight lost can come from lean tissue, particularly without resistance exercise.

This is why structured programmes typically pair these medications with:

• High-protein dietary guidance
• Resistance or strength training
• Regular body composition monitoring

Who Is a Candidate?

Both medications are approved for adults with:

• BMI ≥30 kg/m² (obesity), or
• BMI ≥27 kg/m² (overweight) with at least one weight-related condition (e.g., hypertension, dyslipidaemia, sleep apnoea, pre-diabetes)

Neither is a first-line treatment. Both require medical assessment, baseline investigations, and ongoing clinical supervision.

Frequently Asked Questions

Q: Is tirzepatide better than semaglutide for weight loss? A: Based on the SURMOUNT-5 head-to-head trial, tirzepatide produced approximately 47% greater relative weight loss than semaglutide 2.4 mg at 72 weeks. However, the "best" medication for any individual depends on their health history, comorbidities, and how they respond to treatment. A doctor's assessment is essential.

Q: What is the difference between Zepbound and Wegovy? A: Zepbound contains tirzepatide, a dual GIP/GLP-1 agonist. Wegovy contains semaglutide, a GLP-1 agonist only. Zepbound targets two hormone receptors; Wegovy targets one. Clinical trials show tirzepatide achieves greater average weight loss.

Q: What is the difference between Mounjaro and Ozempic? A: Mounjaro (tirzepatide) and Ozempic (semaglutide) are the diabetes-branded versions of Zepbound and Wegovy respectively. The active ingredients are identical; the approved indications and dose regimens may differ.

Q: Can I switch from Wegovy to Zepbound? A: This is a clinical decision. Some patients do transition between medications. The dose titration would typically restart, and a doctor would guide the switch based on your response, tolerability, and goals.

Q: How long do I need to stay on these medications? A: Both medications are approved for chronic weight management — meaning long-term use. Clinical data suggests that weight is regained when the medication is stopped without lifestyle modification in place. Duration of treatment is a conversation for you and your doctor.

Q: Are these medications available in Singapore? A: Availability and access vary. A licensed weight management clinic can advise on what is currently available, suitable for your profile, and how to access it appropriately.

Summary: Tirzepatide vs Semaglutide at a Glance

Both medications represent a genuine advance in obesity medicine. Tirzepatide's dual-mechanism approach appears to produce superior weight outcomes in direct comparison. The right choice for you depends on your individual medical profile — which is exactly why these medications require prescriber involvement.

Start With a Medical Assessment

Noah is a licensed telehealth weight management service operating in Singapore. Our clinicians assess your eligibility, review your health history, and recommend a structured programme that includes medication where appropriate, alongside nutrition guidance and progress monitoring.

Ready to find out if you're a candidate? **Book a consultation at ofnoah.sg →**